Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • US patent court deals...

    US patent court deals setback to Allergan's Restasis strategy

    Written by Ruby Khatun Khatun Published On 2018-02-28T09:45:52+05:30  |  Updated On 28 Feb 2018 9:45 AM IST
    US patent court deals setback to Allergans Restasis strategy

    A U.S. administrative court said it has the authority to decide the validity of patents Allergan Plc transferred to a Native American tribe, dealing a setback to a strategy the company adopted to protect one of its best-selling medicines from generic competition.


    The Patent Trial and Appeal Board, a court run by the U.S. patent office, declined on Friday a request to dismiss litigation brought by the generic drug company Mylan NV challenging the validity of Allergan’s patents on its dry eye medicine Restasis.


    In September Allergan transferred its patents covering Restasis to the Saint Regis Mohawk Tribe, arguing that the New York-based tribe’s status as a sovereign entity meant the patents could not be reviewed by the board because of a legal doctrine called sovereign immunity.


    “The PTAB’s ruling reinforces our belief that Allergan’s maneuvers to engage the St. Regis Mohawk Tribe for patent protection were a sham,” Mylan Chief Executive Heather Bresch said in a statement.


    Allergan declined to comment.



    Allergan holds patents covering various elements of Restasis that expire in 2024. Rivals were blocked from launching their own versions of the drug until the patents expired or were invalidated in court.

    In 2016 Mylan asked the patent board to invalidate the Restasis patents, saying they described obvious ideas.


    Mylan also asked a federal judge in Texas to invalidate the patents.


    The tribe agreed in September to take legal ownership of the patents and license them back to Allergan in exchange for ongoing payments.


    After announcing the deal the tribe asked the patent board to dismiss the Mylan challenge, saying entities with sovereign immunity cannot face litigation without their consent.


    Allergan has said the patent board is a flawed and unfair forum. The drug company said it would not object to the patents being reviewed in federal court.


    U.S. lawmakers from both political parties have criticized Allergan’s maneuver, with one U.S. senator introducing a bill to ban attempts to take advantage of tribal sovereignty.


    The patent board said in Friday’s ruling that tribal immunity does not apply to patent review proceedings.


    The tribunal also said Allergan had retained an ownership interest in the challenged patents so the proceedings could continue without the tribe’s participation.


    In October the federal judge in Texas invalidated the Restasis patents instead of waiting for the board to rule, rendering Allergan’s move largely meaningless.





    (Reporting by Jan Wolfe; Editing by Susan Thomas)




    Allergandry eye druggeneric drugHeather BreschMylanpatent courtPatent Trial and Appeal BoardRestasisSaint Regis Mohawk tribesetbackUS
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok